[177Lu]Lu-DOTA-NNV003

N/A

Report date: 2025/11/10 17:58:28

Base Information

Drug Name[177Lu]Lu-DOTA-NNV003
Drug Alias Name177Lu-NNV-003NNV-003-[177Lu]chHH1 ARC (Nordic Nanovector)177Lu-NNV-009Lutetium-177-NNV-003 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody +[5] 
Mechanisms of ActionAnti-Leukocyte antigen CD37
TargetsLeukocyte antigen CD37
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorway
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNordic Nanovector Asa
China Registration ClassN/A

Develop Information

Active CompaniesNordic Nanovector Asa
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A